Skip Ribbon Commands
Skip to main content
Clin Assoc Prof Tai Wai Meng David

Clin Assoc Prof Tai Wai Meng David


Senior Consultant

National Cancer Centre Singapore

Specialty: Medical Oncology

Clinical Interest: Hepato-Pancreato-Biliary, Colorectal, Gastrointestinal, Neuroendocrinology

Conditions Treated by this Doctor:
Biliary Cancer, Colorectal Cancer, Liver Cancer, Neuroendocrine Tumours, Oesophageal Cancer, Oesophageal Cancer, Pancreatic Cancer, Stomach Cancer.

Clinical Appointments

  • Senior Consultant Division of Medical Oncology National Cancer Centre SingaporeNational Cancer Centre Singapore

Academic Appointments

  • Duke-NUS Medical School


Dr David Tai is a Senior Consultant Medical Oncologist at National Cancer Centre Singapore. His area of interest is in gastrointestinal cancers and early developmental therapeutics. His research focus involves integrating basic science and translational models in devising new therapy for gastrointestinal malignancies. He is also involved in multiple ongoing trials focusing mainly on gastrointestinal cancers and phase 1 efforts.

Dr Tai is a Clinical Associate Professor in Duke-NUS Medical School, Singapore and faculty for Duke-NUS Fundamental of Clinical Practice Course. He is also a clinical lecturer at Yong Yoo Lin School of Medicine, Singapore. He has participated actively in both undergraduate and postgraduate medical teachings.


  • Specialist Accreditation for Medical Oncology         2011

  • MRCP                                                                         2007

  • MBBS                                                                         2004

Professional Appointments and Committee Memberships

  • Jan 2022 - Present Clinical Associate Professor – Duke NUS
  • Nov 2018 - Present Senior Consultant Medical Oncology
  • Oct 2016 - May 2019 Medical Director of NCCS@CGH Satellite Unit
  • Nov 2013 - Oct 2018 Consultant Medical Oncology
  • Nov 2011 - Oct 2013 Associate Consultant Medical Oncology


  • Singapore Health Quality Service Award 2021 – STAR Award
  • Singapore Health Quality Service Award 2019 – STAR Award
  • Singapore Health Quality Service Award 2018 – Gold Award
  • Singapore Health Quality Service Award 2017 – Silver Award
  • Outstanding Faculty Award Singhealth Residency 2016

Research Interests

  • Translational Research in Gastrointestinal Malignancies with special interests in hepato-pancretico-biliary cancers. 
  • Early Phase Developmental Therapeutics – merging preclinical evidence to rationale design of Phase I trials. 


1)  Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition.
 Sundar R, Huang KK, Kumar V, Ramnarayanan K, Demircioglu D, Her Z, Ong X, Bin Adam    Isa         ZF, Xing M, Tan AL, Tai DWM, Choo SP, Zhai W, Lim JQ, Das Thakur M, Molinero L, Cha E, Fas-so M, Niger M, Pietrantonio F, Lee J, Jeyasekharan AD, Qamra A, Patnala R, Fabritius A, De Simone M, Yeong J, Ng CCY, Rha SY, Narita Y, Muro K, Guo YA, Skanderup AJ, So JBY, Yong WP, Chen Q, Göke J, Tan P. Gut. 2021 Aug 25:gutjnl-2021-324420. [IF: 19.819].

2) Targeted inhibition of FGF19/FGFR cascade improves antitumor immunity and response rate in hepatocellular carcinoma.
    Tai DWM, Le TBU, Prawira A, Ho RZW, Huynh H.Hepatol Int. 2021 Jul 31. [IF: 6.047]

3) A Phase II Single Arm, Single Centre Trial of Y90-Resin Microspheres Radioembolization Followed by Nivolumab in Advanced Hepatocellular Carcinoma– CA 209-678. David Tai, Kelvin Loke, Apoorva Gogna, Neslihan Arife Kaya, Sze Huey Tan, Tiffany Hennedige, Da-vid Ng, Farah Irani, Joycelyn Lee, Jia Qi Lim, Chow Wei Too, Matthew C.H. Ng, Chee Kian Tham, Justina Lam, Si Lin Koo, Hui Shan Chong, George Boon-Bee Goh, Hian Liang Huang, Nanda Venkatanarasimha, Richard Lo, Prof. Pierce K.H. Chow, Prof. Brian K. P. Goh, Prof. Alexander Chung, Han Chong Toh, Prof. Choon Hua Thng, Prof. Tony K.H. Lim, Joe Yeong,  Weiwei Zhai,  Chung Yip Chan, Su Pin Choo. Lancet Gastroenterology and Hepatology (Manuscript accepted). [IF 18.486].

4)  Efficacy and Tolerability of Novel Regimen of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study
 Robin K. Kelley; Bruno Sangro; William Harris; Masafumi Ikeda; Takuji Okusaka; Yoon-Koo Kang; Shukui Qin; David W. M. Tai; Ho Yeong Lim; Thomas Yau; Wei-Peng Yong; Ann-Lii Cheng, MD; Antonio Gasbarrini; Silvia Damian; Jordi Bruix; Mitesh Borad; Johanna Bendell; Tae-You Kim; Na-than Standifer; Philip He; Mallory Makowsky; Alejandra Negro; Masatoshi Kudo and Ghassan K. Abou-Alfa. Journal of Clinical Oncol 2021 Jul 22:JCO2003555. [IF: 44.544].

5)  Non-Terminally Exhausted Tumor-Resident Memory HBV-specific T Cell Responses Corre-late with Relapse-Free Survival in Hepatocellular Carcinoma
 Yang Cheng, Bavani Gunasegaran, Harsimran D. Singh, Charles-Antoine Dutertre, Chiew Yee Loh, Jia Qi Lim, Jeremy Chase Crawford, Hong Kai Lee, Xiaomeng Zhang, Bernett Lee, Etienne Becht, Joe Yeong, Wan Jun Lim, Jerry K.Y. Chan, Florent Ginhoux, David Tai, Jinmiao Chen, Seng Gee Lim, Weiwei Zhai, Su Pin Choo, Evan W. Newell. Immunity. 2021 Aug 10;54(8):1825-1840 [IF: 22.553]

6)  Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Mul-ticenter Retrospective Study.
 Yoo C, Kim JH, Ryu MH, Park SR, Lee D, Kim KM, Shim JH, Lim YS, Lee HC, Lee J, Tai D, Chan SL, Ryoo BY. Liver Cancer. 2021 Apr;10(2):107-114. [IF: 11.740].

7)  Pan-Asian Adapted ESMO Clinical Practice Guidelines for the Management of Patients with Intermediate and Advanced/Relapsed Hepatocellular Carcinoma: A TOS-ESMO Initiative Endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
 Published online 06 JAN 2020 - Ann Oncol (2020) L.T. Chen, E. Martinelli, A.L. Cheng, G. Pentheroudakis, S. Qin, G.S. Bhattacharyya, M. Ikeda, H.Y. Lim, G.F. Ho, S.P. Choo, Z. Ren, H. Malhotra, M. Ueno, B.Y. Ryoo, T.C. Kiang, D. Tai, A. Vogel, A. Cervantes, S.N. Lu, C.J. Yen, Y.H. Huang, S.C. Chen, C. Hsu, Y.C. Shen, J. Tabernero, Y. Yen, C.H. Hsu, T. Yoshino, J.Y. Douillard. [IF: 32.976].

8)  Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsive-ness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma.
 Ng HHM, Lee RY, Goh S, Tay ISY, Lim X, Lee B, Chew V, Li H, Tan B, Lim S, Lim JCT, Au B, Loh JJH, Saraf S, Connolly JE, Loh T, Leow WQ, Lee JJX, Toh HC, Malavasi F, Lee SY, Chow P, Newell EW, Choo SP, Tai D, Yeong J, Lim TKH.J Immunother Cancer. 2020 Aug;8(2):e000987. [IF:13.751]

9) Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer. Lee B, Lipton L, Cohen J, Tie J, Javed AA, Li L, Goldstein D, Burge M, Cooray P, Nagrial A, Tebbutt NC, Thomson B, Nikfarjam M, Harris M, Haydon A, Lawrence B, Tai DWM, Simons K, Lennon AM, Wolfgang CL, Tomasetti C, Papadopoulos N, Kinzler KW, Vogelstein B, Gibbs P. Ann Oncol. 2019 Sep 1;30(9):1472-1478. [IF: 32.976]

10) Clinicopathologic characteristics and survival of patients with gastroenteropancreatic neuroen-docrine neoplasm (GEPNEN) in a multi-ethnic Asian institution
 Tai D, Tan SH, Tan D, Loke K, Ng D, Yan S, Hwang J, Lim KH, Loh LM, Kek PC, Goh B, Lee SY, Chung AYF, Ong S. Neuroendocrinology. 2018 Nov 6. doi: 10.1159/000495140. [IF: 4.271]

Research Trials

• A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination with Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants with Advanced Hepatocellular Carcinoma – CA 209-9DW - Principal Investigator

• Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy (COSMIC-312) - Principal Investigator

• A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarte-rial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carci-noma (EMERALD-1) - Principal Investigator

• A Phase 2, Randomized, Open-label Study of Relatlimab in Combination with Nivolumab in Participants with Advanced Hepatocellular Carcinoma who are Naive to IO Therapy but Pro-gressed on Tyrosine Kinase Inhibitors (RELATIVITY CA224-073) - Principal Investigator

• Phase Ib study evaluating safety and tolerability of combination trametinib and ruxolitinib in patients with advanced RAS mutant colorectal cancer and pancreatic adenocarcinoma – Prin-cipal Investigator (Investigator Initiated Trial)

• A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors- Principal Inves-tigator

• A phase II, open label, randomized, parallel arm study of NIS793 (with and without spartali-zumab) in combination with SOC chemotherapy gemcitabine/ nab-paclitaxel, and gemcita-bine/nab-paclitaxel alone in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) - Principal Investigator